61 results
424B5
LRMR
Larimar Therapeutics Inc
14 Feb 24
Prospectus supplement for primary offering
5:08pm
and reputation.
We do not currently intend to pay dividends on our common stock, and, consequently, investors’ ability to achieve a return
424B5
LRMR
Larimar Therapeutics Inc
13 Feb 24
Prospectus supplement for primary offering
4:46pm
profitability and reputation.
S-11
We do not currently intend to pay dividends on our common stock, and, consequently, investors’ ability to achieve a return
424B5
3zr8fc66ah6d7054ke
14 Sep 22
Prospectus supplement for primary offering
7:28am
8-K
EX-10.1
yk2vwi prxi
30 Oct 20
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-10.1
9qqu7xepf4 f8
6 Aug 20
Departure of Directors or Certain Officers
9:00am
8-K/A
EX-99.2
xottfa4 fhf6j
26 Jun 20
Other Events
5:08pm
8-K
EX-14.1
urxbgdjpf 2esj
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
8-K
EX-10.4
pa6imhiy2fu
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
DEFM14A
gxtkiy
29 Apr 20
Proxy related to merger
3:20pm
PRER14A
y883jukl
10 Apr 20
Preliminary revised proxy
4:38pm